SCHEMBL18189686

SCHEMBL18189686

CCCCCCCCCCCCCCCCn1ccc(C(=O)OCC)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.46
CYP1A2 P05177 2/20 0.45
ALDH1A1 P00352 5/20 0.45
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
KMT2A Q03164 1/20 0.44
THRB P10828 1/20 0.43
PLA2G4A P47712 1/20 0.43
HTT P42858 1/20 0.43
SIRT2 Q8IXJ6 1/20 0.41
KDM4E B2RXH2 2/20 0.41
POLB P06746 1/20 0.41
JMJD6 Q6NYC1 1/20 0.40
LMNA P02545 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
TEAD2 Q15562 1/20 0.40
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17476012 0.94 CYP1A2 (0.47) CNR2CYP1A2ALDH1A1CYP2D6CYP2C9
SCHEMBL31729403 0.89 THRB (0.44) CYP1A2ALDH1A1CYP2D6CYP2C9CYP2C19
SCHEMBL948098 0.88 CYP1A2 (0.50) CYP1A2ALDH1A1CYP2D6CYP2C9CYP2C19
SCHEMBL20046287 0.87 CYP1A2 (0.46) CYP1A2ALDH1A1CYP2D6CYP2C9CYP2C19
SCHEMBL18338543 0.84 THRB (0.45) CYP1A2ALDH1A1CYP2D6CYP2C9CYP2C19
SCHEMBL18338389 0.83 THRB (0.46) CYP1A2ALDH1A1CYP2D6CYP2C9CYP2C19
SCHEMBL11365598 0.83 PLA2G4A (0.54) CYP1A2ALDH1A1CYP2D6CYP2C9CYP2C19
SCHEMBL1739337 0.83 ALDH1A1 (0.61) CYP1A2ALDH1A1CYP2D6CYP2C9CYP2C19
SCHEMBL865041 0.82 CYP1A2 (0.47) CNR2CYP1A2ALDH1A1CYP2D6CYP2C9
SCHEMBL5238571 0.81 ALDH1A1 (0.42) CNR2CYP1A2ALDH1A1CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10568867-B2 Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis GALAPAGOS NV (BE) 2020-02-25 US disclosed
US-20180221334-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS GILEAD SCIENCES, INC. 2018-08-09 US disclosed
US-20160317493-A1 Novel Compounds and Pharmaceutical Compositions Thereof for the Treatment of Cystic Fibrosis GILEAD SCIENCES, INC. 2016-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10568867-B2 Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis CFTR, ABCB11, PKD1 CNR2 336/4885CYP1A2 707/4885ALDH1A1 340/4885
US-20180221334-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS CFTR, ABCB11, ABCC5 CNR2 326/4885CYP1A2 1209/4885ALDH1A1 506/4885
US-20160317493-A1 Novel Compounds and Pharmaceutical Compositions Thereof for the Treatment of Cystic Fibrosis CFTR, ABCB11, ABCC5 CNR2 326/4885CYP1A2 1209/4885ALDH1A1 506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.